Savara Showcases Breakthrough Research on Rare Lung Disease at ERS 2025

Savara Inc. (Nasdaq: SVRA) has announced that three of its research abstracts will be presented at the highly anticipated European Respiratory Society (ERS) Congress 2025, scheduled to take place from September 27 to October 1 in Amsterdam, The Netherlands. The presentations will focus on significant advancements in the understanding and treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare and complex lung disease.

Research Highlights on aPAP

The presentations at the congress will provide valuable insights into the disease burden, treatment efficacy, and diagnostic advancements related to aPAP.

One of the notable studies will be conducted by Dr. Francesco Bonella from Ruhrlandklinik University Hospital. This research explores the relationship between pulmonary gas transfer, respiratory health-related quality of life, exercise capacity, and surfactant burden in patients diagnosed with aPAP. The findings aim to shed light on how these factors interact and affect the daily lives of those affected by the disease.

Additionally, Dr. Cormac McCarthy from University College Dublin will present key findings regarding the efficacy of inhaled molgramostim across various levels of disease severity. This research could significantly impact the treatment landscape for patients suffering from aPAP, offering new options for managing the condition.

The advancements in diagnostics will also be a focal point at the congress. Dr. Eagappanath Thiruppathi from TrilliumBiO will introduce a novel dried serum assay designed to detect GM-CSF antibodies. This tool is expected to enhance diagnostic accuracy for aPAP, which has been a challenge in clinical practice.

Mini Symposium: Advances in aPAP

In addition to the poster presentations, Savara will host an industry-led mini symposium titled “Advances in Autoimmune Pulmonary Alveolar Proteinosis” on September 29. This session will delve into updates on disease pathophysiology, signs and symptoms, the burden of illness, and emerging treatment strategies.

The symposium will feature a distinguished panel of experts, including Dr. Effrosyni D. Manali from the National and Kapodistrian University of Athens, Dr. Maria Molina-Molina from Hospital Universitario de Bellvitge in Spain, and Dr. Maria Kokosi from Royal Brompton Hospital in London. The session will be chaired by Brian Robinson, M.D., Executive Vice President of Global Medical Affairs at Savara.

By presenting these studies and leading discussions at ERS 2025, Savara aims to enhance awareness and advance clinical understanding of autoimmune pulmonary alveolar proteinosis. The company is committed to improving diagnostics and treatment strategies for patients with this often misunderstood disease.

As Savara takes this significant step at the ERS Congress, the spotlight will be on the ongoing efforts to address the challenges faced by aPAP patients. The outcomes of the presentations and symposium discussions may pave the way for new insights and improved care options for those living with this rare lung condition.